Changes in visual evoked potentials in patients with multiple sclerosis treated with isoprinosine and amantadine
- PMID: 2484835
Changes in visual evoked potentials in patients with multiple sclerosis treated with isoprinosine and amantadine
Abstract
We studied 30 patients with clinically definite MS according to the Mc Alpine et al. clinical criteria (20 patients received isoprinosine and 10 amantadine for a period of 12 months). In each patient pattern reversal stimulation was presented to each eye successively and potentials were recorded over both occipital lobes. For each condition the average evoked response to 200 pattern reversals was computed on DISA 2000. During the 24 month-lasting observation high clinical improvement and simultaneous shortening of the latency to peak of the first major positive component of the response in visual evoked potentials was observed in 12 cases with relapsing form treated 12 months with isoprinosine. In 3 cases, despite of the treatment with isoprinosine, new relapses were observed; in these patients delayed response in VEP was observed. In cases treated with amantadine no shortening of the latency to the major positive peak of the potential was observed, also no diminish of relapses frequency was observed.
Similar articles
-
[Changes in pattern evoked visual potentials in multiple sclerosis in respect to development of illness].EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb. 1982 Jun;13(2):73-6. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb. 1982. PMID: 6811242 German.
-
Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis.Cancer Detect Prev Suppl. 1987;1:377-83. Cancer Detect Prev Suppl. 1987. PMID: 2446758 Clinical Trial.
-
Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a.Croat Med J. 2004 Jun;45(3):323-7. Croat Med J. 2004. PMID: 15185427 Clinical Trial.
-
[The value of VEP assessment and immunological csf analysis in the diagnosis of childhood and juvenile MS].Przegl Lek. 2003;60 Suppl 1:1-4. Przegl Lek. 2003. PMID: 12945153 Review. Polish.
-
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis.Neurodegener Dis Manag. 2020 Dec;10(6):383-395. doi: 10.2217/nmt-2020-0030. Epub 2020 Oct 5. Neurodegener Dis Manag. 2020. PMID: 33012266
Cited by
-
A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):164-8. doi: 10.1136/jnnp.57.2.164. J Neurol Neurosurg Psychiatry. 1994. PMID: 7510330 Free PMC article. Clinical Trial.
-
Amantadine for fatigue in multiple sclerosis.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002818. doi: 10.1002/14651858.CD002818.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253480 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical